Retatrutide is an investigational triple-agonist peptide designed to target glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-faceted mechanism aims to provide comprehensive benefits in metabolic regulation, particularly for conditions like obesity and type 2 diabetes.
- Triple Receptor Agonism (GLP-1, GIP, Glucagon)
- Enhanced Glucose Homeostasis
- Significant Weight Management Potential
- Improved Lipid Profiles
- Once-Weekly Administration
| Parameter | Detail |
|---|---|
| Compound Name | Retatrutide |
| Mechanism | GLP-1, GIP, Glucagon Receptor Agonist |
| Administration | Subcutaneous Injection |
| Frequency | Once Weekly |
| Target Conditions | Obesity, Type 2 Diabetes |
| Status | Investigational (Phase 3 Clinical Trials) |
- Comprehensive metabolic control through synergistic pathways.
- Potential for superior weight loss compared to single or dual agonists.
- Improved glycemic control and insulin sensitivity.
- Convenient once-weekly dosing regimen.
As an investigational drug, Retatrutide is currently undergoing rigorous clinical trials. Its safety and efficacy profile are still being evaluated. Patients should consult with healthcare professionals for the latest information and guidance regarding investigational treatments. This information is for educational purposes only and does not constitute medical advice.
For further inquiries about Retatrutide or our research programs, please visit our corporate website or contact our medical affairs department.
